Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Dec;13(4):281-8.
doi: 10.1007/s40268-013-0030-8.

An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report

David Hobbs  1 , Jamie Karagianis, Tamas Treuer, Joel Raskin
Affiliations
Comparative Study

An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report

David Hobbs et al. Drugs R D. 2013 Dec.

Abstract

Background: Orodispersible tablets (ODTs) are tablet or wafer forms of medication that disintegrate in the mouth, aided only by saliva. ODTs rely on different fast dissolve/disintegration manufacturing technologies.

Objectives: Disintegration time differences for several olanzapine ODT forms were investigated. Risperdal M-Tab(®) was included as a non-olanzapine ODT comparator.

Research design and methods: Eleven olanzapine ODT examples and orodispersible risperidone strengths were evaluated in vitro for formulation composition, manufacturing method, disintegration and dissolution characteristics, and formulation differences in comparison with freeze dried Zydis(®) ODT. Automated dissolution test equipment captured ODT dissolution rates by measuring real-time release of active ingredient. A high-speed video camera was used to capture tablet disintegration times in warm simulated saliva.

Main outcome measure: The main outcome measure was the disintegration and dissolution characteristics of the ODT formulations.

Results: The ODT manufacturing method was associated with time to disintegrate; the fastest were freeze dried tablets, followed by soft compressed tablets and then hard/dense tablets. Olanzapine Zydis(®) was the only ODT that completely disintegrated in less than 4 s for all strengths (5, 10, 15, and 20 mg), followed by 5-mg Prolanz FAST(®) (12 s) and then risperidone ODT 4 mg (40 s). Reasons for slow dissolution of the olanzapine generics may include low product potency, excipient binding, excipient solubility, active ingredient particle size and incomplete disintegration.

Conclusions: Differences in the formulation and manufacturing process of olanzapine ODTs appear to have a strong influence on the disintegration time of the active compound; differences that may potentially impact their use in clinical practice.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of 5-mg dissolution data at 30 rpm, up to 3 min. ODT orodispersible tablet
Fig. 2
Fig. 2
Summary of 5-mg dissolution data at 30 rpm, up to 30 min. ODT orodispersible tablet
See this image and copyright information in PMC

References

    1. Mohamed S, Rosenheck R, McEvoy J, et al. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336–346. doi: 10.1093/schbul/sbn067. - DOI - PMC - PubMed
    1. Bitter I, Treuer T, Dilbaz N, et al. Patients’ preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry. 2010;11(7):894–903. doi: 10.3109/15622975.2010.505663. - DOI - PMC - PubMed
    1. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097. doi: 10.1016/S0140-6736(08)60486-9. - DOI - PubMed
    1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223. doi: 10.1056/NEJMoa051688. - DOI - PubMed
    1. Novick D, Haro JM, Suarez D, et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology. 2007;191:1015–1022. doi: 10.1007/s00213-007-0730-2. - DOI - PubMed

Publication types

MeSH terms